Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.95
-2.8%
$1.92
$0.40
$2.66
$261.72M0.41804,186 shs484,266 shs
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$2.73
-5.4%
$3.51
$2.61
$13.99
$252.53M1.241.38 million shs1.04 million shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.59
+0.1%
$3.30
$1.35
$4.60
$276.73M0.941.20 million shs637,450 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.23
+0.7%
$4.78
$3.90
$15.00
$65.94M0.52197,942 shs99,879 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-1.48%-3.85%+19.76%-11.89%+357.25%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-1.03%-11.11%-20.88%-28.71%-65.38%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-5.79%-6.28%-10.05%+69.67%+24.74%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.39%+0.97%+8.58%+5.06%-61.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
$1.95
-2.8%
$1.92
$0.40
$2.66
$261.72M0.41804,186 shs484,266 shs
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$2.73
-5.4%
$3.51
$2.61
$13.99
$252.53M1.241.38 million shs1.04 million shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.59
+0.1%
$3.30
$1.35
$4.60
$276.73M0.941.20 million shs637,450 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$5.23
+0.7%
$4.78
$3.90
$15.00
$65.94M0.52197,942 shs99,879 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-1.48%-3.85%+19.76%-11.89%+357.25%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-1.03%-11.11%-20.88%-28.71%-65.38%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-5.79%-6.28%-10.05%+69.67%+24.74%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.39%+0.97%+8.58%+5.06%-61.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
2.67
Moderate Buy$4.60136.50% Upside
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
2.40
Hold$21.33682.87% Upside
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.40
Hold$9.67169.64% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-4.31% Downside

Current Analyst Ratings Breakdown

Latest LFVN, ELDN, AVXL, and ALXO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
DowngradeSell (D-)Sell (E+)
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
5/4/2026
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Initiated CoverageBuy$20.00
4/22/2026
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
UpgradeSell (E+)Sell (D-)
3/31/2026
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Reiterated RatingBuy$24.00
3/27/2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
Reiterated RatingSell (D-)
3/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
Reiterated RatingHold (C)
3/23/2026
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
Reiterated RatingBuy$24.00
3/19/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Initiated CoverageOverweight$5.00
3/10/2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
Reiterated RatingBuy$4.00
(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/A$0.48 per shareN/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.10 per shareN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.35 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$228.53M0.29$1.11 per share4.70$2.75 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%N/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%N/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4511.618.04N/A2.94%23.89%12.47%N/A

Latest LFVN, ELDN, AVXL, and ALXO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.22-$0.33-$0.11-$0.33N/AN/A
5/8/2026Q1 2026
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$0.15-$0.17-$0.02-$0.17N/AN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/19/2026Q4 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.20-$0.10+$0.10-$0.10N/AN/A
3/9/2026Q4 2025
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/A-$0.42N/A-$0.42N/AN/A
2/27/2026Q4 2025
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
-$0.38-$0.42-$0.04-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
N/AN/AN/AN/AN/A
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.183.44%N/A40.00%3 Years

Latest LFVN, ELDN, AVXL, and ALXO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.054%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
0.02
7.21
7.21
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
20.87
20.87
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
8.44
8.44
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04

Institutional Ownership

CompanyInstitutional Ownership
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
97.97%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
21.00%
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.00%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALX Oncology Holdings Inc. stock logo
ALXO
ALX Oncology
40134.56 million106.31 millionOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4092.67 million82.48 millionOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1077.19 million67.69 millionOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable

Recent News About These Companies

Lifevantage Stock Price History
Lifevantage Q3 Earnings Call Highlights
LifeVantage (LFVN) Q3 2026 Earnings Transcript
LifeVantage Declares Quarterly Dividend
LifeVantage Q3 2026 earnings preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALX Oncology stock logo

ALX Oncology NASDAQ:ALXO

$1.94 -0.06 (-2.75%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Anavex Life Sciences stock logo

Anavex Life Sciences NASDAQ:AVXL

$2.72 -0.16 (-5.38%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$3.58 +0.01 (+0.14%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$5.22 +0.04 (+0.67%)
As of 03:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.